It's been in the development pipeline for a couple of years now, and builds on an approach behind Gardasil so commercialisation, particularly with partnership with a big pharma could expedite the process as they have sufficient resources to fund larger scale P3 studies.
Excellent news regardless
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus HSV-2 Phase II Study Interim Update
Ann: Admedus HSV-2 Phase II Study Interim Update, page-29
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.80 |
Change
-0.760(6.05%) |
Mkt cap ! $249.4M |
Open | High | Low | Value | Volume |
$12.49 | $12.49 | $11.30 | $234.2K | 19.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $11.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.90 | 251 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8 | 12.050 |
1 | 4 | 11.950 |
1 | 500 | 11.850 |
1 | 86 | 11.620 |
2 | 543 | 11.500 |
Price($) | Vol. | No. |
---|---|---|
11.800 | 27 | 1 |
11.900 | 251 | 1 |
12.000 | 312 | 1 |
12.100 | 1220 | 1 |
12.400 | 500 | 1 |
Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |